- Home
- SEMR vs RCUS Comparison
SEMR vs RCUS Comparison
Compare SEMR & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEMR
- RCUS
- Stock Information
- Founded
- SEMR 2008
- RCUS 2015
- Country
- SEMR United States
- RCUS United States
- Employees
- SEMR N/A
- RCUS N/A
- Industry
- SEMR EDP Services
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- SEMR Technology
- RCUS Health Care
- Exchange
- SEMR Nasdaq
- RCUS Nasdaq
- Market Cap
- SEMR 1.2B
- RCUS 1.2B
- IPO Year
- SEMR 2021
- RCUS 2018
- Fundamental
- Price
- SEMR $7.53
- RCUS $11.65
- Analyst Decision
- SEMR Buy
- RCUS Buy
- Analyst Count
- SEMR 8
- RCUS 8
- Target Price
- SEMR $14.88
- RCUS $20.71
- AVG Volume (30 Days)
- SEMR 1.2M
- RCUS 730.3K
- Earning Date
- SEMR 11-06-2025
- RCUS 11-05-2025
- Dividend Yield
- SEMR N/A
- RCUS N/A
- EPS Growth
- SEMR N/A
- RCUS N/A
- EPS
- SEMR N/A
- RCUS N/A
- Revenue
- SEMR $413,962,000.00
- RCUS $262,000,000.00
- Revenue This Year
- SEMR $20.28
- RCUS N/A
- Revenue Next Year
- SEMR $16.41
- RCUS N/A
- P/E Ratio
- SEMR N/A
- RCUS N/A
- Revenue Growth
- SEMR 22.16
- RCUS 6.07
- 52 Week Low
- SEMR $7.01
- RCUS $6.50
- 52 Week High
- SEMR $18.74
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- SEMR 42.14
- RCUS 62.45
- Support Level
- SEMR $7.32
- RCUS $11.04
- Resistance Level
- SEMR $7.90
- RCUS $12.05
- Average True Range (ATR)
- SEMR 0.22
- RCUS 0.57
- MACD
- SEMR 0.02
- RCUS 0.04
- Stochastic Oscillator
- SEMR 25.17
- RCUS 73.73
About SEMR SEMrush Holdings Inc.
SEMrush Holdings Inc is engaged in the online visibility management software-as-a-service (SaaS) platform. Its platform utilizes data and intelligence at the core surrounded by AI-powered interconnected hubs focused on search engine optimization, paid advertising, social media management, local marketing, brand marketing, and content marketing Geographically, it generates revenues from the United States, the UK, and Others.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.